SE9703376D0 - A new combination - Google Patents

A new combination

Info

Publication number
SE9703376D0
SE9703376D0 SE9703376A SE9703376A SE9703376D0 SE 9703376 D0 SE9703376 D0 SE 9703376D0 SE 9703376 A SE9703376 A SE 9703376A SE 9703376 A SE9703376 A SE 9703376A SE 9703376 D0 SE9703376 D0 SE 9703376D0
Authority
SE
Sweden
Prior art keywords
combination
pct
alkyl
enantiomer
sec
Prior art date
Application number
SE9703376A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9703376A priority Critical patent/SE9703376D0/xx
Publication of SE9703376D0 publication Critical patent/SE9703376D0/xx
Priority to ZA987804A priority patent/ZA987804B/xx
Priority to ES98944376T priority patent/ES2222603T3/es
Priority to PL98339368A priority patent/PL339368A1/xx
Priority to KR1020007002830A priority patent/KR20010024084A/ko
Priority to AT98944376T priority patent/ATE270889T1/de
Priority to HU0100621A priority patent/HUP0100621A2/hu
Priority to US09/171,578 priority patent/US6159970A/en
Priority to IL13477598A priority patent/IL134775A0/xx
Priority to EP98944376A priority patent/EP1014986B1/de
Priority to PT98944376T priority patent/PT1014986E/pt
Priority to TR2000/00725T priority patent/TR200000725T2/xx
Priority to JP2000511500A priority patent/JP2001516719A/ja
Priority to CN98811114A priority patent/CN1278727A/zh
Priority to CA002302204A priority patent/CA2302204A1/en
Priority to DK98944376T priority patent/DK1014986T3/da
Priority to AU91931/98A priority patent/AU752719B2/en
Priority to PCT/SE1998/001602 priority patent/WO1999013878A1/en
Priority to SK283-2000A priority patent/SK2832000A3/sk
Priority to EEP200000146A priority patent/EE200000146A/xx
Priority to BR9812236-3A priority patent/BR9812236A/pt
Priority to MXPA00002616A priority patent/MXPA00002616A/es
Priority to DE69825062T priority patent/DE69825062T2/de
Priority to IDW20000522D priority patent/ID25789A/id
Priority to KR1020007002835A priority patent/KR20010024087A/ko
Priority to ARP980104635A priority patent/AR013503A1/es
Priority to IS5401A priority patent/IS5401A/is
Priority to NO20001400A priority patent/NO20001400L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9703376A 1997-09-18 1997-09-18 A new combination SE9703376D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination
ZA987804A ZA987804B (en) 1997-09-18 1998-08-27 A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist
KR1020007002835A KR20010024087A (ko) 1997-09-18 1998-09-09 모노아민 옥시다제 억제제 및 ｈ5-ＨＴ1Ｂ 길항제 또는부분 작용제의 배합물
JP2000511500A JP2001516719A (ja) 1997-09-18 1998-09-09 モノアミンオキシダーゼ阻害剤およびｈ５−ＨＴ１Ｂアンタゴニストまたは部分的アゴニストの組み合わせ
DK98944376T DK1014986T3 (da) 1997-09-18 1998-09-09 Kombination af en inhibitor for monoaminoxidase og en antagonist eller delvis agonist for h5-HT 1 beta
KR1020007002830A KR20010024084A (ko) 1997-09-18 1998-09-09 모노아민 옥시다제 억제제 및 ｈ5-ＨＴ1Ｂ 길항제 또는부분 작용제의 배합물
AT98944376T ATE270889T1 (de) 1997-09-18 1998-09-09 Monoaminoxidase inhibitor- und h5-ht 1 beta antagonist oder partiellagonist enthaltende mischung
HU0100621A HUP0100621A2 (hu) 1997-09-18 1998-09-09 Monoamin oxidáz inhibitor hatású vegyületek és h5-HT1B antagonista vagy részleges agonista hatású vegyületek kombinációját tartalmazó gyógyászati készítmények
US09/171,578 US6159970A (en) 1997-09-18 1998-09-09 Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist
IL13477598A IL134775A0 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
EP98944376A EP1014986B1 (de) 1997-09-18 1998-09-09 Monoaminoxidase inhibitor- und h5-ht 1 beta antagonist oder partiellagonist enthaltende mischung
PT98944376T PT1014986E (pt) 1997-09-18 1998-09-09 Uma combinacao de um inibidor da monoamino-oxidase e de um antagonista ou de umagonista parcial do h5-ht 1 beta
TR2000/00725T TR200000725T2 (tr) 1997-09-18 1998-09-09 Bir monoamin oksidaz inhibitörü ve h5-HT1B antagonistinin bileşimi
ES98944376T ES2222603T3 (es) 1997-09-18 1998-09-09 Una combinacion de un inhibidor de la monoamino-oxidasa y un antagonista o agonista parcial de h5-ht1 beta.
CN98811114A CN1278727A (zh) 1997-09-18 1998-09-09 单胺氧化酶抑制剂和h5－ht1B拮抗剂或部分激动剂的组合
CA002302204A CA2302204A1 (en) 1997-09-18 1998-09-09 A combination of a monoamine oxidase inhibitor and a h5-ht1b antagonist or partial agonist
PL98339368A PL339368A1 (en) 1997-09-18 1998-09-09 Composition of monoamine oxidase inhibitor and antagonist or partial agonist of h5-ht 1b
AU91931/98A AU752719B2 (en) 1997-09-18 1998-09-09 A combination of a monoamine oxidase inhibitor and a h5-HT 1B antagonist or partial agonist
PCT/SE1998/001602 WO1999013878A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
SK283-2000A SK2832000A3 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A H5-HT1Bì (54) ANTAGONIST OR PARTIAL AGONIST
EEP200000146A EE200000146A (et) 1997-09-18 1998-09-09 Monoamiini oksüdaasi inhibiitori kombinatsioon h5-HT 1B antagonisti või osalise agonistiga
BR9812236-3A BR9812236A (pt) 1997-09-18 1998-09-09 Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit
MXPA00002616A MXPA00002616A (es) 1997-09-18 1998-09-09 Combinacion de un inhibidor de la monoamina-oxidasa y un antagonista o agonista parcial de h5-ht1b.
DE69825062T DE69825062T2 (de) 1997-09-18 1998-09-09 Monoaminoxidase inhibitor- und h5-ht 1 beta antagonist oder partiellagonist enthaltende mischung
IDW20000522D ID25789A (id) 1997-09-18 1998-09-09 KOMBINASI DARI INHIBITOR MONOAMINA OKSIDASI DAN ANTAGONIS ATAU SEBAGIAN AGONIS h5-HT1B
ARP980104635A AR013503A1 (es) 1997-09-18 1998-09-17 Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion
IS5401A IS5401A (is) 1997-09-18 2000-03-14 Samsetning mónóamínoxídasa hemils og h5-HT1B mótlyfs eða gerandefnis með hlutaverkun
NO20001400A NO20001400L (no) 1997-09-18 2000-03-17 Kombinasjon av en monoaminooksidaseinhibitor og en h5-HT1B antagonist eller partiell agonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (1)

Publication Number Publication Date
SE9703376D0 true SE9703376D0 (sv) 1997-09-18

Family

ID=20408296

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination

Country Status (27)

Country Link
US (1) US6159970A (de)
EP (1) EP1014986B1 (de)
JP (1) JP2001516719A (de)
KR (2) KR20010024087A (de)
CN (1) CN1278727A (de)
AR (1) AR013503A1 (de)
AT (1) ATE270889T1 (de)
AU (1) AU752719B2 (de)
BR (1) BR9812236A (de)
CA (1) CA2302204A1 (de)
DE (1) DE69825062T2 (de)
DK (1) DK1014986T3 (de)
EE (1) EE200000146A (de)
ES (1) ES2222603T3 (de)
HU (1) HUP0100621A2 (de)
ID (1) ID25789A (de)
IL (1) IL134775A0 (de)
IS (1) IS5401A (de)
MX (1) MXPA00002616A (de)
NO (1) NO20001400L (de)
PL (1) PL339368A1 (de)
PT (1) PT1014986E (de)
SE (1) SE9703376D0 (de)
SK (1) SK2832000A3 (de)
TR (1) TR200000725T2 (de)
WO (1) WO1999013878A1 (de)
ZA (1) ZA987804B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957948A (en) * 1988-05-05 1990-09-18 Interface, Inc. Biocidal protective coating for heat exchanger coils
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP2009533325A (ja) * 2006-03-17 2009-09-17 アストラゼネカ・アクチエボラーグ ５−ｈｔ６調節剤としての新規なテトラリン
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (de) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazolderivate als glutaminylcyclase-hemmer
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110179988A (zh) * 2019-07-10 2019-08-30 王大伟 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用
IL321485A (en) * 2022-12-14 2025-08-01 Luminous Mind Inc Treatment of psychological symptoms affecting other medical conditions (PFAOMC)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT533268E (pt) * 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
IL134775A0 (en) 2001-04-30
MXPA00002616A (es) 2002-04-24
TR200000725T2 (tr) 2000-08-21
PT1014986E (pt) 2004-10-29
DK1014986T3 (da) 2004-10-25
PL339368A1 (en) 2000-12-18
AR013503A1 (es) 2000-12-27
EE200000146A (et) 2001-02-15
DE69825062D1 (de) 2004-08-19
ES2222603T3 (es) 2005-02-01
KR20010024084A (ko) 2001-03-26
AU752719B2 (en) 2002-09-26
ATE270889T1 (de) 2004-07-15
CN1278727A (zh) 2001-01-03
ID25789A (id) 2000-11-02
KR20010024087A (ko) 2001-03-26
IS5401A (is) 2000-03-14
EP1014986B1 (de) 2004-07-14
SK2832000A3 (en) 2000-09-12
ZA987804B (en) 1999-03-18
EP1014986A1 (de) 2000-07-05
HUP0100621A2 (hu) 2001-08-28
CA2302204A1 (en) 1999-03-25
NO20001400L (no) 2000-05-05
BR9812236A (pt) 2000-07-18
JP2001516719A (ja) 2001-10-02
WO1999013878A1 (en) 1999-03-25
NO20001400D0 (no) 2000-03-17
AU9193198A (en) 1999-04-05
DE69825062T2 (de) 2005-08-25
US6159970A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
SE9703375D0 (sv) A new combination
SE9703376D0 (sv) A new combination
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
EA200401172A1 (ru) Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии
EE9700282A (et) Bensimidasooli ühendid, nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
DK0635015T3 (da) Acylaminoindolderivater som 5-Htl agonister
SE9603283D0 (sv) New compounds
PE20001234A1 (es) Compuestos azabiciclicos sustituidos de heteroaril-aminoetil/benzisoxazol como antagonistas serotonergicos 5-ht1
SE9703374D0 (sv) A new combination
FI945582A0 (fi) Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina
SE9804126D0 (sv) New pharmaceutical composition
SE9702534D0 (sv) Compounds
DK0885004T3 (da) Anvendelse af 4-phenyl-3,6-dihydro-2H-pyridyl-derivater som NMDA-receptor-undertypeblokkere
TW429147B (en) Pharmaceutical composition for the treatment of CNS disorders
DK0687257T3 (da) 4-amino-2-(hetero)aryl-butanamider anvendelige som 5HT1A-antagonister
DK0667860T3 (da) Azaspiroalkan-derivater som terapeutiske midler
TH51661A (th) สารรวมของสารยับยั้งการดูดกลับของ 5-HT และแอนทาโกนิสท์หรืออะโกนิสท์บางส่วน h5-HTIB